Our Technology
One of the core tenets of our belief in the Athebody technology is a simple existence proof: biological organisms – including humans – use repeat proteins as the most versatile binding proteins from cell cycle control to immune response regulation. Using this blueprint from nature, Athebody® DARPins should be able to provide meaningful solutions where specific targeting is key. For example, we successfully applied our Athebody technology in partnerships to develop targeted-AAV or LNP, pHLA-binding TCEs or targeted radiotherapy.
Athebody DARPins
Based on clinically validated DARPins (>2500 patients dosed)
Small protein scaffold (15 kDa), no S-S bridges
Fully modular binding domain (i) enabling multi-specific binding or (ii) providing targeting moieties to other modalities
Easily linkable at N and C termini enabling dual- & multi-conjugation or protein fusions
Exceptional high target specificity
Highly soluble, no aggregation, exceptional high thermal and chemical stability
Rapid, simple and cost-efficient bacterial-based CMC
For extracellular AND intracellular applications
Drug Discovery engine
Fully in vitro selection system allowing tight control of target quality
High functional library diversity, yielding a diversity of binders to maximize pre-clinical and clinical success